Eli Lilly & Co Dossier
Qualitative Analysis
Business overview
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical leader founded in 1876 and incorporated in Indiana. The company discovers, develops, manufactures, and markets human pharmaceutical products globally. Lilly operates in a single business segment but maintains a highly diversified therapeutic focus spanning cardiometabolic health, oncology, immunology, and neuroscience. The company has established itself as the dominant force in the metabolic and obesity treatment landscape, driven by its blockbuster dual GIP/GLP-1 receptor agonist tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. Beyond metabolic disease, Lilly is expanding its footprint in neuroscience with Kisunla (donanemab) for early symptomatic Alzheimer's disease, alongside a robust portfolio of immunology and oncology treatments.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Lilly is adding manufacturing capacity across its Lebanon, Indiana campus, including its first dedicated genetic-medicine facility, a future API site and the planned Lilly Medicine Foundry. The facilities are intended to support advanced therapies, tirzepatide, Foundayo and retatrutide.
Expected impact: Expand clinical and commercial production capacity, support high-demand cardiometabolic products and create an integrated path from research-stage genetic medicines to large-scale commercial supply.
Lilly completed the Phase 3 clinical-data package supporting global registrations of retatrutide for obesity, obstructive sleep apnea and knee-osteoarthritis pain after reporting positive results from three additional Phase 3 obesity trials.
Expected impact: Potentially add a next-generation triple GIP, GLP-1 and glucagon receptor agonist to Lilly's obesity franchise and address multiple obesity-related complications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Adds an orexin receptor 2 agonist portfolio led by cleminorexton and expands Lilly's neuroscience capabilities into narcolepsy and other sleep-wake disorders. The stated value is maximum potential aggregate equity consideration: approximately $6.3 billion upfront plus contingent value rights worth up to approximately $1.5 billion.
Adds Kelonia's in vivo gene-placement platform and KLN-1010, an investigational anti-BCMA in vivo CAR-T therapy for multiple myeloma. The stated value is maximum potential cash consideration, including $3.25 billion upfront and milestone-contingent payments.
Adds AJ1-11095, an investigational Type II JAK2 inhibitor for myelofibrosis and polycythemia vera, strengthening Lilly's blood-cancer pipeline. The stated value is maximum potential cash consideration, including upfront and clinical or regulatory milestone payments.
Adds engineered circular-RNA and lipid-nanoparticle technology, including ORN-252, an in vivo CD19 CAR-T candidate for B-cell-driven autoimmune diseases. The stated value is maximum potential cash consideration, including upfront and clinical-development milestone payments.
Establishes a shingles-vaccine program led by amezosvatein, designed to preserve immune response while improving tolerability and potentially increasing vaccination completion. The stated value is maximum potential cash consideration.
Adds a bacterial-vaccine platform targeting pathogens affected by antimicrobial resistance, led by the Phase 1 LTB-SA7 Staphylococcus aureus vaccine. The stated value is maximum potential cash consideration.
Adds in vivo nanoparticle technology and a Phase 1-ready, five-antigen Epstein-Barr virus vaccine candidate, expanding Lilly into prevention of infections associated with neurological and oncological consequences. The stated value is maximum potential cash consideration.
Strategic Partnerships
Combines Lilly's biological, chemical, clinical and manufacturing expertise and proprietary data with NVIDIA's AI models, accelerated computing, BioNeMo platform, robotics and digital-twin technologies.
Terms: The companies plan to invest jointly up to $1 billion over five years in talent, infrastructure and compute for the South San Francisco Bay Area laboratory.